Appointments, Network Agreements, Earnings Results Schedules, and Legal Claims - Analyst Notes on Alexion, Humana, Eli Lilly, Teva and Cigna

NEW YORK, April 23, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), Humana Inc. (NYSE: HUM), Eli Lilly & Co. (NYSE: LLY), Teva Pharmaceutical Industries Limited (NYSE: TEVA) and Cigna Corp (NYSE: CI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1465-100free.

--
Alexion Pharmaceuticals, Inc. Analyst Notes
On April 17, 2014, Alexion Pharmaceuticals, Inc. (Alexion) named John "Jack" T. Mollen to the Company's Board of Directors, with immediate effect. The Company also announced that Joseph A. Madri, Ph.D., M.D. and Larry L. Mathis, will retire at the end of the current term on May 5, 2014, after serving for 22 years and 10 years, respectively. Commenting on the appointment, Max Link, Ph.D. Chairman of Alexion's Board of Directors, said, "Jack has a remarkable track record as a leader and executive and brings substantial operational experience in human resources and organizational development to the Alexion Board. His expertise will be valuable to our growing global organization and we are pleased to welcome him to the Alexion Board of Directors." The full analyst notes on Alexion are available to download free of charge at:

http://www.analystsreview.com/1465-ALXN-23Apr2014.pdf

--
Humana Inc. Analyst Notes
On April 16, 2014, Humana Inc. (Humana) announced that the Company has reached an agreement that provides its members access to Dignity Health facilities in Arizona. The new network agreement, commencing on May 1, 2014, includes Humana's Medicare Advantage (including PPO, HMO and Private Fee for Service plans), employer groups and individual plan members. Brendan Baker, Arizona Market President for Humana's Senior Products, said, ""Humana has a strong Medicare Advantage presence in Arizona. Expanding our network to include Dignity Health will offer our members a strong provider network and is key to our continued growth in the market." The full analyst notes on Humana are available to download free of charge at:

http://www.analystsreview.com/1465-HUM-23Apr2014.pdf

--
Eli Lilly & Co. Analyst Notes
On April 10, 2014, Eli Lilly & Co. (Eli Lilly) announced that it will release its financial results for Q1 2014 on April 24, 2014, before market opening. Eli Lilly informed that it will also conduct a conference call on that day with the investment community and media to provide further detail of the Company's financial performance, from 9:00 a.m. to 10:00 a.m. EDT. According to Zacks Investment Research, the consensus EPS estimate for Q1 2014 is $0.70. The pharma Company reported adjusted net income, excluding items, of $796.9 million or $0.74 per share for Q4 2013. Worldwide total revenue for Q4 2013 was $5.8 billion, ahead of Wall Street analysts' consensus estimate of $5.46 billion. The full analyst notes on Eli Lilly are available to download free of charge at:

http://www.analystsreview.com/1465-LLY-23Apr2014.pdf

--
Teva Pharmaceutical Industries Limited Analyst Notes
On April 19, 2014, Teva Pharmaceutical Industries Limited (Teva) informed that its application to stay the Federal Circuit's decision for COPAXONE patent due to the potential for the Company to recover patent infringement damages has been denied by the Chief Justice of the U.S. However, the Chief Justice found that the Company had demonstrated "a fair prospect of success on the merits" in its appeal of a decision from the United States Court of Appeals for the Federal Circuit that invalidated the claim of U.S. Patent 5,800,808 (808 patent). Teva stated that the 808 patent expires on September 1, 2015 and it is confident that COPAXONE will remain a market leading product for the reduction in the frequency of relapses in relapsing-remitting multiple sclerosis patients over the product's lifecycle, given the strength of its intellectual property rights. The Company intends to continue pursuing its appeal in the Supreme Court. The full analyst notes on Teva are available to download free of charge at:

http://www.analystsreview.com/1465-TEVA-23Apr2014.pdf

--
Cigna Corp Analyst Notes
On April 17, 2014, Cigna Corp. (Cigna) announced the celebration of its 20 years as a sponsor of the March of Dimes. Over this 20 year period, Cigna, the Cigna Foundation, Cigna employees and their friends and families have contributed more than $28.5 million supporting the charity's efforts to help mothers have full-term pregnancies. In its 20th year, the Company hopes to raise record amounts to help the March of Dimes continue its mission. Cigna's President & CEO, David Cordani, commented, "With our growing global presence and our intensifying focus on helping individuals take control of their personal health, Cigna remains committed to finding innovative solutions for the health challenges faced by mothers and their newborns." The full analyst notes on Cigna are available to download free of charge at:

http://www.analystsreview.com/1465-CI-23Apr2014.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review. An outsourced research services provider represented by Namrata Maheshwari, CFA, has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

AnalystsReview.com

SOURCE Analysts Review